Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech, Inc. (Nasdaq: IOBT) is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. This news page aggregates company announcements, clinical updates, financial disclosures, and regulatory communications related to IO Biotech and its lead investigational cancer vaccine candidate, Cylembio® (IO102-IO103).
Readers can find coverage of clinical trial milestones, including data from the pivotal Phase 3 IOB-013/KN-D18 trial of Cylembio plus KEYTRUDA® (pembrolizumab) in advanced melanoma and Phase 2 basket trials in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and other solid tumors. News items also highlight long-term outcomes from earlier-phase studies, such as the MM1636 Phase 1/2 trial, and pre-clinical data for additional T-win platform candidates IO112 and IO170.
Investors and followers of IOBT can review regulatory and corporate updates, including the company’s reports on FDA interactions regarding Cylembio, workforce restructuring plans, and participation in major medical and investor conferences. Financial press releases provide quarterly results, operating expense trends, cash position commentary, and details on financing arrangements such as the European Investment Bank term loan facility and associated warrants.
This page is useful for tracking how IO Biotech communicates progress on its immune-modulatory cancer vaccine programs, interprets key efficacy and safety results, and describes its ongoing engagement with regulators and collaborators. For those monitoring IOBT stock or the broader immuno-oncology field, the news feed offers a centralized view of the company’s scientific presentations, trial readouts, and strategic business developments over time.
IO Biotech has announced the initiation of a Phase 2 clinical trial to evaluate the safety and efficacy of its lead candidate, IO102-IO103, in combination with KEYTRUDA (pembrolizumab) for treating metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, and metastatic urothelial bladder cancer. This collaboration with Merck follows previous successful trials and aims to expand on the candidate's potential utility across multiple tumor types. IO Biotech retains global commercial rights to IO102-IO103.
IO Biotech has successfully closed its initial public offering (IPO), issuing 8,222,500 shares at $14.00 each, raising approximately $115.1 million before expenses. This includes the underwriters’ full option to purchase an additional 1,072,500 shares. The shares began trading on the Nasdaq under the symbol IOBT on November 5, 2021. Morgan Stanley, Jefferies, and Cowen acted as joint lead managers for the offering. The funds raised will support the development of IO Biotech's novel cancer therapies based on its T-win® technology.
IO Biotech announced the pricing of its initial public offering (IPO) of 7,150,000 shares at $14.00 per share, totaling approximately $100.1 million before fees. Trading is set to begin on Nasdaq under the symbol IOBT on November 5, 2021, with the offering closing expected on November 9, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 1,072,500 additional shares. The offering is led by Morgan Stanley, Jefferies, and Cowen.